BCN PEPTIDES

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 24 Dec 2024 filing date already counts against anyone who files later.

Record

Serial number

79417399

Mark type

Word mark

Filed

24 Dec 2024

Published for opposition

08 Sept 2026

Attorney of record

Elizabeth Lee D'Amore

Goods and services

• Class 001 — Chemicals: Chemical products for use in industry specifically for biotechnological product development; chemical products for use in pharmaceutical product manufacture; chemical products for manufacturing cosmetics; biological preparations for industry and science
• Class 005 — Pharmaceuticals: Pharmaceutical products, namely, pharmaceutical preparations for the treatment of cardiovascular diseases, of the central nervous system, namely, encephalitis, epilepsy, alzheimer's, cerebral palsy, parkinson's disease, of respiratory diseases, namely, respiratory infections, asthma, bronchitis, pneumonia, of eating disorders, of musculo-skeletal disorders, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, of urological, urogenital and urinary disorders, of dermatological diseases, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, rosacea, blotches; pharmaceutical products for medical use to treat metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases, gynecological conditions and conditions of the reproductive system; pharmaceutical products for veterinary use, namely, veterinary pharmaceutical preparations for the treatment of metabolic disorders, immune conditions and disorders, inflammatory conditions, pain, infectious diseases, oncological conditions, endocrine disorders, neurological disorders, cardiovascular diseases and disorders, hematological diseases, respiratory diseases, ophthalmic diseases, diseases of the digestive system, dermatological conditions and disorders, urological diseases and conditions of the reproductive system; pharmaceutical products for skin care; hygienic and sanitary products for medical use namely, disinfectants and sanitary sterilizing preparations; dietetic substances for medical use; dietetic substances namely, dietetic preparations adapted for veterinary use, food supplements for humans and animals; biological preparations for medical and veterinary use specifically cytostatic agents, hormones, diagnostic agents for medical purposes, anti-infective agents, blood clotting agents, blood anticoagulant agents, , veterinary pharmaceutical preparations for the treatment of infectious diseases, namely, swine dysentery, bacterial enteritis, bluecomb, pneumonia, respiratory infections, eye infections, topical infections
• Class 042 — Scientific and technological services: Scientific and technological services as well as research and design related thereto, namely, scientific research, development, and design services relating to pharmaceuticals; industrial analysis and research services in the field of chemistry for medical purposese; pharmaceutical research services; research and development services in chemistry; research services relating to cosmetics; pharmaceutical research and product development services

Owner

• BCN PEPTIDES, S.A., ES
• BCN PEPTIDES, S.A., ES

Prosecution history

• 08 Sept 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 08 Sept 2026 — PUBLISHED FOR OPPOSITION
• 02 Sept 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 12 Aug 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 06 Aug 2026 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
• 03 Aug 2026 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
• 20 Jul 2026 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
• 19 Jul 2026 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
• 03 Feb 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
• 03 Feb 2026 — LETTER OF SUSPENSION E-MAILED
• 03 Feb 2026 — SUSPENSION LETTER WRITTEN
• 02 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 02 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 02 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 23 Aug 2025 — REFUSAL PROCESSED BY IB